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Abstract 
Introduction and objectives. Recently, there have been many developments in the management of nonvalvular atrial 
fibrillation, antiarrhythmic and anticoagulant therapy, and nonpharmacological treatment, but these developments are 
not applied immediately in clinical practice. The aim of this study was to identify the overall management and 
antiarrhythmic therapy used in the current general population of patients with nonvalvular atrial fibrillation in Spain. 
Methods. A prospective, observational study of 1318 consecutive anticoagulated patients with nonvalvular atrial 
fibrillation, recruited between June 2013 and March 2014. We analyzed the patients’ general characteristics, 
management, and antiarrhythmic therapy. 
Results. Mean age was 73.8 ± 9.4 years; 42.5% were women. Atrial fibrillation was paroxysmal in 28% of the 
patients, permanent in 50%, persistent in 17.6%, long-standing persistent in 4.5%, and new-onset in 66 patients (5%). 
A rhythm control strategy was chosen in 39.4% of the patients and rate control in 60.6%. Beta-blockers were 
prescribed in 60.2% of the patients, digoxin in 19.5%, and calcium channel antagonists in 10.7%. The antiarrhythmic 
agents used were amiodarone (12.6%), flecainide (8.9%), propafenone (0.4%), sotalol (0.5%), and dronedarone 
(2.3%). Cardioversion had been performed previously in 41.9% of the patients, ablation in 3.4%, and atrial 
appendage closure in 0.2%. 
Conclusions. Currently, patients with nonvalvular atrial fibrillation in Spain are managed mainly with rate control, 
and beta-blockers in particular. They receive few antiarrhythmic agents and only a very small number of these 
patients undergo nonpharmacological treatments. 
Resumen 
Introducción y objetivos. Recientemente se han producido numerosas novedades en el manejo de la fibrilación 
auricular no valvular y el tratamiento antiarrítmico, anticoagulante y no farmacológico empleado, pero su aplicación a 
la clínica no es inmediata. El objetivo del trabajo es conocer las características generales de manejo y tratamiento 
antiarrítmico de una población general de pacientes con fibrilación auricular no valvular actualmente en España. 
Métodos. Estudio observacional y prospectivo de 1.318 pacientes consecutivos con fibrilación auricular no valvular, 
anticoagulados y reclutados entre junio de 2013 y marzo de 2014. Se analizan sus características generales, el manejo 
y el tratamiento antiarrítmico utilizado. 
Resultados. La media de edad era 73,8 ± 9,4 años; eran mujeres el 42,5%. La fibrilación auricular fue paroxística en 
el 28% de los casos, permanente en el 50%, persistente en el 17,6%, persistente de larga duración en el 4,5% y de 
novo en 66 pacientes (5%). Se eligió control del ritmo en el 39,4% de los casos y de frecuencia en el 60,6%. Tomaron 
bloqueadores beta el 60,2%, digoxina el 19,5% y antagonistas del calcio el 10,7%. Los antiarrítmicos empleados 
fueron amiodarona (12,6%), flecainida (8,9%), propafenona (0,4%), sotalol (0,5%) y dronedarona (2,3%). Se realizó 
cardioversión previa en el 41,9%, ablación en el 3,4% y cierre de orejuela en el 0,2%. 
Conclusiones. Actualmente en nuestro país se maneja a los pacientes con fibrilación auricular no valvular 
preferentemente con control de frecuencia, sobre todo con bloqueadores beta, reciben pocos antiarrítmicos y se los 
somete en muy baja proporción a tratamientos no farmacológicos. 
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Introduction 
Atrial fibrillation (AF) is the most common arrhythmia in Western countries. Prevalence, estimated at 
1.5% to 2%,1 increases with age, ranging from 1% in individuals younger than 60 years to 12% in the 
group aged 75 to 84 years. More than a third of patients with AF are aged 80 years or older.1 and 2 
Recently, the Spanish OFRECE study estimated that AF prevalence in Spain was 4.4% in adults older 
than 40 years and 17.7% in those aged 80 or older.3 This arrhythmia is often associated with structural 
heart disease and other chronic conditions. It leads to significant morbidity and mortality (increased 
mortality and stroke risk, heart failure [HF], dementia, etc), and increased hospital admissions and 
economic burden.2, 4, 5, 6, 7, 8, 9 and 10 
Since 2010, European and US guidelines on AF have been published almost yearly, reflecting the 
major changes in the management of patients with this condition. This whirlwind of changes is the result 
of the successive introduction of more discriminative embolism and bleeding risk indices, the key role of 
implantable cardiac devices in silent AF, novel oral anticoagulants (OAC) and new antiarrhythmic agents, 
and the development of ablation. Recently, nonvalvular atrial fibrillation (NVAF) has been defined as AF 
in the absence of rheumatic mitral stenosis, heart valve prosthesis, or mitral valve repair.1 Clinical 
practice guidelines show general consensus in their recommendations, which reflect these major changes 
in overall management, and pharmacological and nonpharmacological decisions (such as whether to 
follow a rhythm or rate control strategy in initial NVAF management, and indications for classic and new 
antiarrhythmic agents).11 However, these guidelines are not immediately applied in routine clinical 
practice, despite their strong clinical trial-based evidence and high class of recommendation. 
The aim of this study was to analyze the current management of NVAF, choice of rhythm or rate 
control strategies, and the use of antiarrhythmic therapy and nonpharmacological treatment in a general, 
unselected population of patients with NVAF in Spain. 
Methods 
Study Data and Design 
The data for this study were taken from the FANTASIIA Registry (Spanish acronym for Atrial 
fibrillation: Influence of anticoagulation level and type on stroke and bleeding event incidence), a 
prospective, observational, national, multicenter study that is collecting general information on the current 
situation and characteristics of the Spanish population with any type of NVAF, following the European 
AF guideline criteria.1 The main aim of the registry is to evaluate the incidence of thromboembolic and 
bleeding events in an unselected population of patients with NVAF over 3 years, specifically with 
reference to the use and type of antithrombotic agent, vitamin K antagonist (VKA) and direct OAC, as 
well as anticoagulation adjustment (in patients receiving VKA). The FANTASIIA Registry is designed as 
an initial enrolment visit and 3 follow-up visits at 1, 2, and 3 years. The patients’ clinical and laboratory 
data are being collected in an electronic case report form. 
In our study, we analyzed a cross-sectional baseline data set from the FANTASIIA enrolment visit, 
focusing on the secondary endpoints of the registry, which concern the general characteristics of NVAF 
management, initial AF control strategy, rhythm or rate control, treatment type, antiarrhythmic class, and 
nonpharmacological treatment. 
Study Population 
In this preliminary analysis, we studied 1318 consecutive patients, seen at 50 outpatient clinics, with a 
diagnosis of NVAF (excluding patients with rheumatic mitral valve disease or valvular prostheses), 
entered in the FANTASIIA Registry by 81 investigators (81% cardiologists, 11% primary care 
physicians, and 8% internists) between June 2013 and March 2014. The clinics were randomly selected, 
and located throughout Spain. Inclusion criteria were patients older than 18 years who had been receiving 
anticoagulant therapy (80% VKA and 20% direct OAC, ie, dabigatran, rivaroxaban or apixaban) for at 
least 6 months before enrolment. The patients were managed according to routine clinical practice. The 
FANTASIIA Registry complies with all the principles of the Declaration of Helsinki and the study 
protocol was approved by the Clinical Research Ethics Committee at Hospital Universitario de Alicante 
and by all the local ethics committees. All study participants signed the informed consent. 
Statistical Analysis 
Quantitative variables were described using the mean ± standard deviation or median [interquartile 
range], depending on whether they followed a normal distribution, which we tested with the Kolmogorov-
Smirnov method. For between-group comparisons, we used the Student t test for continuous variables and 
the chi-square test for qualitative variables. Statistical significance was defined as P < .05. Statistical 
analyses were performed with SPSS statistical package version 12. 
Results 
Baseline Characteristics of Study Patients 
We enrolled 1318 patients throughout Spain who met the aforementioned inclusion and exclusion criteria 
between June 2013 and March 2014. Baseline characteristics are shown in Table 1. Mean age was 73.8 
years (± 9.4 years) and 758 patients (57.5%) were men. The most prevalent risk factor was hypertension, 
which was observed in 1068 patients (81.0%), followed by hypercholesterolemia in 711 (54.0%), and 
diabetes mellitus in 386 (29.0%). Other notable comorbidities were ischemic stroke, in 210 patients 
(15.9%), and major bleeding, in 44 (3.3%). At the initiation visit, most patients, n = 948 (71.9%), were 
treated with acenocoumarol, 68 (5.2%) with warfarin, and 303 (23.0%) with a novel direct OAC. Left 
atrial appendage closure had been performed in 3 patients (0.2%). Mean scores for thromboembolic and 
bleeding risk indices were: CHADS2, 2.32; CHA2DS2-VASc, 3.79, and HAS-BLED, 1.99. CHA2DS2-
VASc = 0 was found in 4.9% of the patients; CHA2DS2-VASc = 1 in 24.1%, and CHA2DS2-VASc ≥ 2 in 
71% of the patients. HAS-BLED score was < 3 and ≥ 3 in 72.4% and 27.6% of the patients, respectively. 
Antiplatelets were used in 126 patients (9.8%), aspirin in 95 (7.4%), clopidogrel in 21 (1.6%), prasugrel 
in 1 (0.1%), and dual antiplatelet therapy was used in 9 patients (0.8%). 
  
Table 1. Baseline Characteristics of the Study Population 
  
Patients 1318 
Women 560 (42.5) 
Age, years 73.8 ± 9.4 
Age ≥ 75 years 689 (52.3) 
Cardiovascular risk factors  
Hypertension 1068 (81.0) 
Hypercholesterolemia 711 (54.0) 
Diabetes mellitus 386 (29.3) 
Smoker 60 (4.6) 
Concomitant disease  
Renal disorder 251 (19.0) 
Hepatic impairment 13 (1.0) 
COPD and/or sleep apnea 222 (16.8) 
Peripheral vascular disease 92 (7.0) 
Previous stroke 210 (15.9) 
Thyroid dysfunction 173 (13.1) 
Alcohol or drug use 210 (15.9) 
Major bleeding 44 (3.3) 
Previous heart disease 629 (47.7) 
Heart failure 376 (28.5) 
Coronary artery disease 245 (18.6) 
CHADS2  
0 64 (4.9) 
1 318 (24.1) 
≥ 2 936 (71.0) 
CHA2DS2-VASc  
0 16 (1.2) 
1 86 (6.5) 
≥ 2 1216 (92.3) 
HAS-BLED ≥ 3 363 (27.7) 
Concomitant treatment  
Diuretics 784 (59.5) 
ACE inhibitor 411 (31.2) 
ARB 540 (41.0) 
Statins 742 (56.3) 
Antiplatelets 130 (9.9) 
Anticoagulation therapy  
Vitamin K antagonists 1016 (77.1) 
Acenocoumarol 948 (71.9) 
Warfarin 68 (5.2) 
Novel direct anticoagulants 303 (23.0) 
  
 
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; CHADS2: heart failure, hypertension, age ≥ 75 years, 
diabetes mellitus, ictus/transient ischemic attack; COPD, chronic obstructive pulmonary disease; HAS-BLED: hypertension, 
abnormal renal/liver function, stroke, recent bleeding history or predisposition, labile international normalized ratio, elderly, use of 
drugs predisposing to bleeding/alcohol abuse; VASc: vascular disease, age 65 to 74 years, female sex. 
Data are expressed as no. (%) or mean ± standard deviation. 
Type of Atrial Fibrillation and Type of Control Strategy Chosen 
Atrial fibrillation was paroxysmal in 367 patients (28%), permanent in 656 (50%), persistent in 231 
(17.6%) and long-standing persistent in 59 (4.5%). New-onset AF was found in 66 patients (5%). Time 
since AF diagnosis was 3.2 years (1.8 years). Nearly a third of the patients (32.2%) were in sinus rhythm 
at the baseline visit. A rhythm control strategy was chosen in 39.4% of the patients (45.3% of the patients 
younger than 75 years and 30.2% aged 75 years or older). A rate control strategy was chosen in 60.6% 
(54.7% younger than 75 years and 69.8% aged 75 years or older) (P < .001). Cardioversion had been 
performed previously in 41.9% (electrical cardioversion in 19%, pharmacological cardioversion in 
22.9%). Ablation had been performed previously in 3.4% (2.2% for paroxysmal AF, 1.3% for persistent 
AF, and 0.15% for long-standing persistent AF). Table 2 shows the characteristics of patients classified 
by rhythm or rate control strategy. Patients who received rhythm control were younger, had a lower 
prevalence of diabetes mellitus, chronic obstructive pulmonary disease, renal impairment and HF, and a 
higher prevalence of thyroid dysfunction history. The modified Charlson comorbidity index was lower in 
this group. Rhythm control was chosen in 44.1% of the patients seen by cardiologists and in 19.2% seen 
by internists or primary care physicians (P < .001). There were no significant differences for the other 
variables analyzed ( Table 2). 
Table 2. Characteristics of Patients Classified by Rhythm or Rate Control Strategy 
 Rhythm control Rate control P 
    
Patients (n = 1318) 39.4 60.6  
Age, years 71.0 ± 9.3 75.5 ± 9.0 < .001 
Women 44.5 41.2 .240 
Comorbidities and CVRF    
History of hypertension 80.5 81.7 .589 
History of hyperlipidemia 55.5 53.0 .375 
Diabetes mellitus 25.3 31.9 .011 
Current smoker 5.22 4.1 .361 
COPD/OSA 12.9 19.5 .002 
Kidney disease 16.0 20.9 .026 
Dialysis 0.2 0.9 .119 
Liver disorder 0.9 1.0 .946 
Cancer 7.2 9.1 .198 
Aortic or lower limb arterial disease 6.0 7.5 .283 
Previous stroke 16.1 18.8 .196 
Previous noncerebral embolism 2.1 2.6 .558 
Thyroid dysfunction 16.6 10.8 .002 
Use of drugs predisposing to bleeding or alcohol 
abuse 
2.9 4.6 .113 
Modified Charlson comorbidity index 0.98 ± 1.11 1.27 ± 1.20 < .001 
Heart history    
Previous heart disease 45.2 49.5 .133 
Heart failure 24.7 33.1 .001 
Previous coronary disease 19.3 18.2 .609 
Previous acute coronary syndrome 15.4 14.1 .482 
Previous coronary revascularization 10.8 11.1 .899 
Dilated cardiomyopathy 11.8 12.5 .680 
Hypertrophic cardiomyopathy 2.7 2.7 .952 
Chronic pericardial disease 0.2 0.4 .556 
Aortic valve disease 2.1 2.9 .396 
HT-induced left ventricular hypertrophy 15.4 16.7 .553 
Previous bradyarrhythmia 6.3 6.6 .844 
Previous ablation 3.8 2.4 .122 
Pacemaker 6.0 7.7 .248 
    
 
COPD, chronic obstructive pulmonary disease; CVRF, cardiovascular risk factors; HT, hypertension; OSA, obstructive sleep apnea. 
Data are expressed as a percentage or mean ± standard deviation. 
Antiarrhythmic and Rate Control Agents Used 
Antiarrhythmic agents were only used in 24.7% of patients. The drugs most frequently used for heart 
rhythm control were amiodarone (12.6%), flecainide (8.9%), propafenone (0.4%), sotalol (0.5%), and 
dronedarone (2.3%). The drugs most commonly used for heart rate control were beta-blockers (60.2%), 
digoxin (19.5%), and calcium channel antagonists (verapamil or diltiazem) (10.7%). Table 3 shows the 
number of patients receiving each drug alone and in combination, in the whole group and by rhythm and 
rate subgroups. No patients received a combination of 2 or more Class I or III antiarrhythmic agents, 
while 13.9% received a combination of 2 or more rate-slowing drugs (6.5%) or an antiarrhythmic plus a 
rate-slowing drug (7.4%). The most common combinations were an antiarrhythmic plus beta-blocker, and 
beta-blocker plus digoxin (Table 3). Antiarrhythmic agents were more common in the rhythm control 
group (55.9% vs just 4.5% in the rate control group; P < .001), and rate-slowing drugs were more 
common in the rate control group (92.4% vs 68.5% in the rhythm control group; P < .001). The 
combination of antiarrhythmic and rate-slowing drugs was more common in the rhythm control group 
(15.4% vs 0.7% in the rate control group, P < .001), and the combination of different rate-slowing drugs 
was more common in the rate control group (10.4% vs 2.9% in the rhythm control group; P < .001) ( 
Table 3). 
  
Table 3. Antiarrhythmic and Rate-slowing Drugs, Alone and in Combination, in the Total Group and by Rhythm and Rate Control 
Subgroups 
 Total Rhythm control Rate control P 
     
Patients, n 1318 520 798  
Individual drugs     
Antiarrhythmics 24.7 55.9 4.5 < .001 
Ic (flecainide/propafenone) 9.3 21.8 1.3 < .01 
III (amiodarone/dronedarone/sotalol) 15.4 34.1 3.2 < .001 
Rate-slowing drugs 82.9 68.5 92.4 < .001 
BB 60.2 52.5 65.2 < .05 
Digoxin 19.5 11.5 24.7 < .05 
Calcium channel antagonists (verapamil/diltiazem) 10.7 7.3 12.9 .08 
Drug combinations     
> 1 antiarrhythmic agent 0 0 0  
> 1 rate-slowing drug 7.4 2.9 10.4 < .05 
BB + digoxin + calcium channel antagonist 0 0 0  
BB + digoxin 4.4 2.1 5.9 .282 
BB + calcium channel antagonist 0.9 0.2 1.3 .579 
Digoxin + calcium channel antagonist 2.3 0.4 3.2 .170 
Antiarrhythmic + rate-slowing drug 6.5 6.5 0.7 < .01 
Antiarrhythmic + BB 4.1 9.6 0.5 < .01 
Antiarrhythmic + digoxin 2.3 5.0 0.3 < .05 
Antiarrhythmic + calcium channel antagonist 0.3 0.8 0 .653 
     
 
BB, beta-blockers. 
Data are expressed as a percentage unless otherwise indicated. 
We also observed differences in the type of drugs used according to left ventricular ejection fraction 
(LVEF) function. The LVEF was < 45% in 206 patients (15.6% of the total) and ≥ 45% in the remaining 
1112 patients (84.4%). The rhythm control strategy was less common among patients with reduced LVEF 
(29.1% vs 41.4%; P < .001). The rate control strategy was more common in both groups, with a marked 
difference in the reduced LVEF group (70.9% vs 58.6%; P < .001). Table 4 shows the distribution of 
antiarrhythmic agents by LVEF function. Among patients with reduced LVEF, the use of class III 
antiarrhythmics was more common than class Ic antiarrhythmics (15.5% vs 0.5%). Beta-blockers were 
the most commonly used rate-slowing drug in both groups. Digoxin was the most frequently used drug in 
patients with reduced LVEF function. 
Table 4. Management and Antiarrhythmic Agents Used, Classified by Reduced (< 45%) or Preserved (≥ 45%) Left Ventricular 
Ejection Fraction 
 Total LVEF < 45% LVEF ≥ 45% P 
     
Patients, n 1318 206 1112  
Control strategy     
Rhythm control 39.4 29.1 41.4 < .001 
Rate control 60.6 70.9 58.6 < .001 
Antiarrhythmics 24.7 16.0 26.2 < .01 
Ic (flecainide/propafenone) 9.3 0.5 10.9 < .05 
III (amiodarone/dronedarone/sotalol) 15.4 15.5 15.3 .965 
Rate-slowing drugs 82.9 67.9 85.7 < .01 
Beta-blockers 60.2 50.5 61.9 < .05 
Digoxin 19.5 26.2 18.2 < .05 
Calcium channel antagonists (verapamil/diltiazem) 10.7 2.9 12.1 < .05 
     
 
LVEF, left ventricular ejection fraction. 
Data are expressed as a percentage unless otherwise indicated. 
  
Differences Between Patients Seen by Cardiologists or Noncardiologists 
Table 5 shows the characteristics and management of patients seen by cardiologists (1066 patients 
[80.8%]) and internists or primary care physicians (252 [19.2%]). There were no relevant between-group 
differences in most patient characteristics, except for older age, a higher prevalence of diabetes mellitus 
and renal impairment, and a slightly higher modified Charlson comorbidity index in patients seen by 
cardiologists. The prevalence of other cardiovascular risk factors, comorbidities and associated heart 
diseases (including coronary disease and HF) was similar in both groups (Table 5). As mentioned earlier, 
rhythm control strategy was significantly less common among patients seen by internists or primary care 
physicians. Cardiologists used more antiarrhythmic agents (class Ic and III alike), while internists and 
primary care physicians used more rate control drugs (Table 5). We observed differences in the type of 
rate-slower drug used: cardiologists used beta-blockers much more, and internists and primary care 
physicians used digoxin more. 
Table 5. Characteristics of Patients Seen by Cardiologists, or Internists and Primary Care Physicians 
 Cardiologist I/PCP P 
    
Patients (n = 1318) 80.8 19.2  
Age, years 72.8 ± 49.3 77.6 ± 8.8 < .001 
Women 41.1 48.4 .034 
Comorbidities and CVRF    
History of hypertension 80.7 82.54 .497 
History of hyperlipidemia 52.7 59.1 .067 
Diabetes mellitus 27.7 36.1 .008 
Current smoker 4.5 4.8 .976 
COPD/OSA 16.5 18.2 .506 
Kidney disease 17.9 23.8 .032 
Dialysis 0.6 0.4 .633 
Liver disorder 1.0 0.7 .731 
Cancer 8.1 9.1 .618 
Aortic or lower limb arterial disease 6.7 7.9 .508 
Previous stroke 17.0 20.6 .183 
Previous noncerebral embolism 2.2 3.1 .392 
Thyroid dysfunction 13.7 10.71 .207 
Alcohol or drug use 3.28 6.75 .011 
Modified Charlson comorbidity index 1.1 ± 1.2 1.3 ± 1.2 .027 
Heart history    
Previous heart disease 48.8 42.8 .085 
Heart failure 29.2 32.1 .370 
Previous coronary disease 19.3 15.4 .158 
Previous acute coronary syndrome 14.9 13.1 .461 
Previous coronary revascularization 11.4 8.7 .214 
Dilated cardiomyopathy 13.7 5.9 .001 
Hypertrophic cardiomyopathy 3.38 0 .003 
Chronic pericardial disease 0.2 0.4 .765 
Aortic valve disease 2.2 3.9 .122 
HT-induced left ventricular hypertrophy 16.5 14.6 .478 
Previous bradyarrhythmia 6.3 7.1 .659 
Previous ablation 3.2 1.5 .153 
Pacemaker 6.2 9.9 .042 
Management and antiarrhythmic agents    
Rhythm control strategy 44.1 19.2 < .001 
Rate control strategy 55.9 80.8 < .001 
Antiarrhythmics (Ic or III) 27.4 13.1 < .001 
Flecainide/propafenone 10.4 4.0 < .001 
Amiodarone/dronedarone/sotalol 16.7 9.0 < .001 
Rate-slowing drugs 81.4 89.2 < .001 
Beta-blockers 69.3 21.4 < .001 
Digoxin 9.4 62.3 < .001 
Calcium channel antagonists 10.3 12.3 .363 
    
 
COPD, chronic obstructive pulmonary disease; HT, hypertension; I, internist; OSA, obstructive sleep apnea; PCP, primary care 
physician. 
Data are expressed as a percentage or mean ± standard deviation unless otherwise indicated. 
  
Discussion 
The aim of NVAF management is 2-fold: to reduce patients’ symptoms and prevent the serious 
complications of this condition. These 2 goals should be achieved simultaneously. The prevention of AV-
related complications is based on antithrombotic treatment, ventricular heart rate control and appropriate 
treatment of concomitant heart diseases. These measures alone may be sufficient to control symptoms, 
but symptomatic relief may also require additional rhythm control treatment by means of electrical or 
pharmacological cardioversion, or ablation. This cross-sectional analysis of NVAF data from the 
FANTASIIA Registry describes the characteristics of NVAF management in terms of treatment and 
antiarrhythmic management (choice of rhythm or rate control strategy, and use of pharmacological and 
nonpharmacological antiarrhythmic treatment). In our series, 28% of patients had paroxysmal NVAF and 
50% had permanent NVAF, which was the most common type. These figures are similar to those 
described in other recent studies.1, 8, 9 and 10 The rate control strategy was used more than the rhythm 
control strategy, in 60% and 39% of patients, respectively. The preference for rate control was also 
observed in all analyzed subgroups, as shown in Table 2, although the lower use of rhythm control was 
more significant in older patients and those with comorbidities such as diabetes mellitus, chronic 
obstructive pulmonary disease, and renal impairment, and in patients with HF and reduced LVEF (< 
45%) (Table 4). Rhythm control was also used less in patients seen by internists or primary care 
physicians (19.2% vs 44% of patients seen by cardiologists; P < .001). This lower preference for the 
rhythm control strategy may be explained by the results of studies showing nonsuperiority of rhythm over 
rate control. 11, 12, 13, 14 and 15 
For example, the AFFIRM study11 did not observe superiority of either strategy with regard to reduced 
mortality or stroke. The 2 strategies were also found to be similar in the RACE study12 in terms of 
cardiovascular mortality among patients with AF and HF. This finding was repeated in the AF-CHF 
study,13 with cardiovascular mortality among patients with AF and LVEF < 35%. The AFFIRM,11 
RACE12 PIAF,14 and STAF15 studies all found similar benefits from using rhythm vs rate control 
strategies in terms of quality of life. A more recent study,16 which enrolled more than 5000 unselected, 
community-based patients patients, has also confirmed the findings of the earlier studies. As Anguita et al 
have already observed,17 it appears contradictory that clinical practice guidelines continue to recommend 
rhythm control over rate control in their indications, without clear evidence in this respect.1 and 2 Our 
study, however, found that in clinical practice, Spanish physicians show a preference for the rate control 
strategy. This preference is reasonable, considering the high mean age of the study population. The rate 
control strategy was used significantly more by noncardiologists than cardiologists (Table 5). However, 
these findings may be biased by the characteristics of the FANTASIIA population (advanced age, high 
prevalence of comorbidities and heart disease, low incidence of new-onset AF, chronic anticoagulant use, 
etc). The rhythm control strategy might have been more frequently chosen if the patient population were 
younger, with fewer comorbidities and no chronic anticoagulant use, as found in recent studies.8, 9 and 10 
Antiarrhythmic agents (Ic and III) were an uncommon choice in our study, accounting for just a 
quarter of the overall sample, possibly reflecting the low percentage of patients with the rhythm control 
strategy (Table 3). Of the antiarrhythmic agents used, amiodarone was the most common (12.6% of 
patients), followed by flecainide (8.9%), dronedarone (2.3%), sotalol (0.5%), and propafenone (0.4%). 
This preference for amiodarone matches clinical practice guideline recommendations,1 and 2 which clearly 
state that amiodarone is the most effective and safest antiarrhythmic agent for maintaining sinus rhythm 
in patients who absolutely require this treatment, and particularly in those with severe structural heart 
disease and/or advanced or unstable HF.1 and 17 Other authors18 and 19 draw on their clinical experience to 
conclude that, although noncardiac side effects of amiodarone are greater than those of other 
antiarrhythmic agents, at the dosage used in AF and with close monitoring, these side effects can be 
reduced to a minimum or resolved in most patients simply by discontinuing the drug. The low percentage 
of dronedarone use in our setting appears to be reasonable in view of the current recommendations of the 
European Medicines Agency20 and results of the ANDROMEDA21 and PALLAS22 studies. Also, in the 
only study comparing 2 antiarrhythmics, dronedarone was inferior to amiodarone in preventing AF 
recurrence (63.5% vs 42%).23 In our study, class Ic antiarrhythmics were not very common, and they 
were hardly used at all in patients with reduced LVEF, as recommended in clinical practice 
guidelines.1 and 2 No patients received a combination of antiarrhythmics. Some patients, however, received 
a combination of antiarrhythmic and rate-slowing drugs, and beta-blockers and digoxin, in particular, in 
the rhythm control group (15.4% of the total of this subgroup) (Table 3). 
The most commonly used drugs for heart rate control in our study were beta-blockers (in 60.2% of the 
patients), digoxin (19.5%), and calcium channel antagonists (10.7%). This coincides with clinical practice 
guidelines that indicate preferential use of beta-blockers with a class I strength of recommendation and B 
level of evidence.1 and 2 Cardiologists used beta-blockers more than other rate-slowing drugs, while 
internists and primary care physicians used digoxin more. The use of beta-blockers and digoxin was 
similar in reduced and preserved LVEF (Table 4). These data match those observed in other recent studies 
in Europe.8 and 9 
In our study, cardioversion had previously been performed in 41.9% of the patients (electrical 
cardioversion in 19%, pharmacological cardioversion in 22.9%). Ablation in AF had been performed in 
only 3.4% of the patients, with the highest percentage in paroxysmal AF. The ablation figure may seem 
low, but the guidelines recommend precaution with this approach,1 and 2 and recent European registries in 
the general population with AF show similar figures of about 5% to 7%.8, 9 and 10 
Study Limitations 
This study is a preliminary analysis of the baseline data in the FANTASIIA Registry, which is still 
underway. We need to wait until registry closure, scheduled for 2016, to perform a more detailed and 
appropriate analysis of the management, strategies and antiarrhythmic agents used for NVAF in Spain, 
because these variables will change over time, according to the clinical course of each patient. Another 
limitation is that by design, this study analyses drug treatment at the time of the enrollment visit, and does 
not include drug history or changes. 
Conclusions 
Currently, anticoagulated patients with any type of NVAF in Spain are mostly elderly, and more are 
treated with a rate control strategy than a rhythm control strategy. Beta-blockers are prescribed most in 
the rate control drug group. These patients receive few antiarrhythmic agents (amiodarone being the most 
common), and a very low percentage undergo nonpharmacological treatments such as ablation. 
Funding 
The FANTASIIA Registry receives an unrestricted grant from Pfizer/Bristol-Myers-Squibb. 
Conflicts of interest 
None declared. 
References 
1. A.J. Camm, G.Y.H. Lip, R. de Caterina, I. Savelieva, D. Atar, S.H. Hohnloser, et al. 2012 focused update of the 
ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the 
management of atrial fibrillation developed with the special contribution of the European Heart Rhythm 
Association Authors/Task Force Members. Eur Heart J., 33 (2012), pp. 2719–2747. 
2. C.T. January, L.S. Wann, J.S. Alpert, H. Calkins, J.C. Cleveland Jr., J.E. Cigarroa, et al. 2014 AHA/ACC/HRS 
Guideline for the Management of Patients With Atrial Fibrillation: A report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. 
Circulation., 130 (2014), pp. 199–267.  
3. J.J. Gómez-Doblas, J. Muñiz, J.J. Alonso Martin, G. Rodríguez-Roca, J.M. Lobos, P. Awanleh, on behalf of the 
OFRECE study researchers, et al. Prevalencia de fibrilación auricular en España. Resultados del estudio 
OFRECE. Rev Esp Cardiol., 67 (2014), pp. 259–269. 
4. P.S. Miller, F.L. Andersson, L. Kalra. Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation 
underestimated?. Stroke., 36 (2005), pp. 360–366. 
5. T.J. Wang, M.G. Larson, D. Levy, R.S. Vasan, E.P. Leip, P.A. Wolf, et al. Temporal relations of atrial fibrillation 
and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation., 107 
(2003), pp. 2920–2925. 
6. A.D. Krahn, J. Manfreda, R.B. Tate, F.A. Mathewson, T.E. Cuddy. The natural history of atrial fibrillation: 
incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med., 98 (1995), pp. 476–484. 
7. S. Stewart, C.L. Hart, D.J. Hole, J.J. McMurray. A population-based study of the long-term risks associated with 
atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med., 113 (2002), pp. 359–364. 
8. P. Kirchchof, B. Ammentorp, H. Darius, R. De Caterina, J.Y. Le Heuzey, R.J. Schilling, et al. Management of 
atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial 
fibrillation: primary results of the PREFER in AF. Europace., 16 (2014), pp. 6–14 
9. G.Y.H. Lip, C. Laroche, G.A. Dan, M. Santini, Z. Kalarus, L.H. Rasmussen, et al. A prospective survey in 
European Society of Cardiology member countries of atrial fibrillation management: baseline results of EORP-
AF Pilot General Registry. Europace., 16 (2014), pp. 308–319. 
10. G.Y.H. Lip, C. Laroche, P.M. Ioachim, L.H. Rasmussen, L. Vitali-Serdoz, L. Petrescu, et al. Prognosis and 
treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EORP-AF Pilot 
registry. Eur Heart J., 35 (2014), pp. 3365–3376. 
View Record in Scopus 
11. D.G. Wyse, A.L. Waldo, J.P. Demarco, M.J. Domanski, Y. Rosenberg, E.B. Schron, AFFIRM Investigators, et al. 
A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med., 347 (2002), 
pp. 1825–1833. 
12. I.C. Van Gelder, V.E. Hagens, H.A. Bosker, H. Kingma, O. Kamp, T. Kingma, et al. A comparison of rate control 
and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med., 347 (2002), pp. 1834–
1840. 
13. D. Roy, M. Talajic, S. Nattel, D.G. Wyse, P. Dorian, K.L. Lee, et al. Rhythm control versus rate control for atrial 
fibrillation and heart failure. N Engl J Med., 358 (2008), pp. 2667–2677. 
14. S.H. Hohnloser, K.H. Kuck, J. Lilienthal. Rhythm or rate control in atrial fibrillation. Pharmacological 
intervention in atrial fibrillation (PIAF): a randomised trial. Lancet., 356 (2000), pp. 1789–1794. 
15. J. Carlsson, S. Miketic, J. Windeler, A. Cuneo, S. Haun, S. Micus, et al. Randomized trial of rate-control in 
persistent atrial fibrillation. J Am Coll Cardiol., 41 (2003), pp. 1690–1696. 
16. A.J. Camm, G. Breithardt, H. Crijns, P. Dorian, P. Kowey, J.Y. Le Heuzey, et al. Real life observations of clinical 
outcomes with rhythm- and rate-control therapies for atrial fibrillation RECORDAF (Registry on Cardiac 
Rhythm Disorders Assessing the Control of Atrial Fibrillation). J Am Coll Cardiol., 58 (2011), pp. 493–501. 
17. M. Anguita, F. Worner, P. Domenech, F. Marín, J. Ortigosa, Pérez-Villacastín, et al. Nuevas evidencias, nuevas 
controversias: análisis crítico de la guía de práctica clínica sobre fibrilación auricular 2010 de la Sociedad 
Europea de Cardiología. Rev Esp Cardiol., 65 (2012), pp. 7–13. 
18. L. Benito, J. Hoyo, A. Montroig, B. Fornés, G. Fluxaá, D. Martí, et al. Estudio sobre los efectos adversos de los 
fármacos antiarrítmicos en pacientes con fibrilación auricular atendidos en un Centro de Atención Primaria. Med 
Clin (Barc)., 137 (2011), pp. 241–246. 
19. L. Van Erven, M.J. Schalij. Amiodarone: an effective antiarrhythmic drug with unusual side effects. Heart., 96 
(2010), pp. 1593–1600. 
20. Dronedarona (MultaqW): conclusiones de la revaluación de su relación beneficio riesgo [nota informativa 
16/2011]. Available at: 
http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2011. 
21. L. Kober, Torp-Pedersen Ch, J.J. McMurray, O. Gotzsche, S. Lévy, H. Crijns, et al. Increased mortality after 
dronedarone therapy for severe heart failure. N Engl J Med., 358 (2008), pp. 2678–2687. 
22. S.J. Connolly, A.J. Camm, J.L. Halperin, C. Joyner, M. Alings, J. Amerena, PALLAS Investigators, et al. 
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med., 365 (2011), pp. 2268–2276. 
23. J. Le Heuzey, G.M. De Ferrari, D. Radzik, M. Santini, J. Zhu, J.M. Davy. A short-term, ramdomized, double-
blind, parallel group study to evaluate the efficacy and safety of dronedorone versus amiodarone in patients with 
persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol., 21 (2010), pp. 597–605. 
 
